Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was KRW 7 million compared to KRW 4.72 million a year ago. Net loss was KRW 48,527.97 million compared to net income of KRW 1,179.36 million a year ago. Basic loss per share from continuing operations was KRW 1,227 compared to basic earnings per share from continuing operations of KRW 36.1538 a year ago. Diluted loss per share from continuing operations was KRW 1,227 compared to diluted earnings per share from continuing operations of KRW 36.1538 a year ago. Basic loss per share was KRW 1,227 compared to basic earnings per share of KRW 47 a year ago.